This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    30/04/19

    Venetoclax in the treatment of chronic lymphocytic leukemia

    Areas covered: This article reviews the chemical structure, mechanisms of action, pharmacokinetic, and the clinical applications of venetoclax in monotherapy and in combined treatment of CLL.

    • Source: Expert Opinion on Drug Metabolism & Toxicology
    Journals
    Journal
    24/04/19

    Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...

    • Source: Blood
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/02/17

    NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche

    The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/06/22

    NICE (UK)recommends venetoclax for treatment of chronic lymphocytic leukemia.

    The National Institute for Health and Care Excellence (NICE)(UK); Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic leukaemia (CLL) in adults

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/04/25

    Calquence Approved for CLL

    CHMP gives positive opinion on marketing authorization variation for Calquence in combination with venetoclax for untreated CLL.

    Journals
    Journal
    15/02/19

    Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

    Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi?centre retrospective analysis of 105 R/R CLL patients who received venetoclax...

    • Source: British Journal of Haematology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/12/24

    Calquence + venetoclax improves survival in untreated CLL

    The AMPLIFY Phase III trial results show that fixed-duration Calquence (acalabrutinib) plus venetoclax significantly improves progression-free survival compared to standard care in untreated chronic lymphocytic leukemia

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/10/16

    EU CHMP recommends approval of Venclyxto (venetoclax) for chronic lymphocytic leukaemia- AbbVie

    The EU's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/03/18

    Results of Phase III Murano trial of Venclexta + Rituxan in chronic lymphocytic leukaemia published in NEJM.- AbbVie/Roche/Genentech.

    Results from the Phase III Murano trial of Venclexta (venetoclax) from AbbVie, and Rituxan (rituximab), from Roche/Genentech, significantly improved progression-free...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    19/01/16

    FDA and EMA accept filing of venetoclax for the treatment of chronic lymphocytic leukemia (CLL) - AbbVie

    AbbVie announced that the FDA has accepted AbbVie's New Drug Application (NDA) granting priority review for venetoclax for the treatment...

    See more